Brief: Faes Farma To License Bilastine In The United States

Faes Farma SA

21/09/2021 06:29

Sept 21 (Reuters) - Faes Farma  FAE.MC :
    * SAID ON MONDAY IT SIGNED LICENSE AGREEMENT FOR BILASTINE
WITH
HIKMA SPECIALTY USA INC FOR THE UNITED STATES OF AMERICA
    * UNDER THE AGREEMENT FAES WILL RECEIVE UPFRONT PAYMENT FOR
NET
VALUE OF 3.5 MILLION DOLLARS (2.98 MILLION EUROS), DOUBLE-DIGIT
ROYALTIES AND MILESTONE PAYMENTS 
    * HIKMA WILL ACT AS FAES FARMA'S AGENT IN PROCESSING
APPLICATION
FOR REGISTRATION IN THE COUNTRY AND WILL BE RESPONSIBLE FOR THE
PROMOTION AND COMMERCIALIZATION AFTER APPROVAL
    * THE COMPANY ALSO REPORTS RECENT REGULATORY APPROVAL OF
BILASTINE
IN AUSTRALIA
    * IT IS ALSO REPORTED THAT OFFICIAL APPLICATION FOR
REGISTRATION
IN CHINA IS EXPECTED TO BE FILED AT THE END OF 2021 OR EARLY
2022

    
    
 Source text for Eikon:  urn:newsml:reuters.com:*:nCNM47px1v
    
 Further company coverage:  FAE.MC  
   



(1 euro = $1.1731)

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))